The global biodefense market size was estimated to be USD 16.17 billion in 2023 and is expected to reach at USD 30.19 billion by 2034 with a CAGR of 5.84% during the forecast period 2024-2034. Rising investment from major market players, growing government focus & funding towards biodefense strategies, increasing prevalence of various agents such as the Ebola virus, Zika virus, & flu, surge in technological advancements in the field of genetic engineering & biotechnology, rising prevalence of infectious diseases, growing research & development activities for the development of novel vaccines, surge in launch of advanced products, and increasing regulatory approvals of biodefense products are some of the key factors boosting the market growth.
Increasing regulatory approvals of biodefense products is predicted to boost the market growth during the forecast period. Biodefense encompasses a range of medical and military actions implemented to safeguard a nation's biosecurity against biological toxins or infectious agents. These agents may be employed with the aim of causing harm or infection in humans, animals, or the environment, potentially leading to acts of biological warfare. Typically, the biological agents utilized in bioterrorism involve living organisms such as bacteria, viruses, fungi, or toxins that are deliberately harnessed to induce illness and casualties, thereby causing social and economic disruption. For instance, in July 2023, Emergent BioSolutions Inc. has announced that the U.S. Food and Drug Administration (FDA) has given its approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909. This approval covers the use of CYFENDUS for post-exposure prophylaxis in individuals aged 18 to 65 who are suspected or confirmed to have been exposed to Bacillus anthracis, provided it is administered in conjunction with the recommended antibacterial drugs.
By product, anthrax was the highest revenue-grossing segment in the global biodefense market in 2023 owing to the surge in anthrax outbreaks within the human population, rising favorable government initiatives, growing research & development partnerships in the respective areas of study, increasing mergers & acquisitions. For instance, in April 2022, Elusys Therapeutics, Inc., a biodefense business with commercial operations, has been formally acquired by Heat Biologics, Inc. Elusys is renowned for its development of the anthrax therapy ANTHIM (obiltoxaximab), which has received approval for use not only in the United States and Canada but also in Europe and the United Kingdom, where it is marketed as Obiltoxaximab SFL. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of infection cases attributed to the Zika and Ebola viruses, growing focus on the development of novel vaccines, and increasing research & development activities.
By detection device, assay was the highest revenue-grossing segment in the global biodefense market in 2023 owing to the increasing utilization of immunological assays, including techniques including Polymerase Chain Reaction (PCR), Immunochromatographic Tests (ICT), Next-Generation Sequencing (NGS) technology, & real-time RT-PCR and surge in research & development efforts. Additionally, identifier is predicted to grow at fastest CAGR during the forecast period. The identifier is the most crucial element of the detection architecture as it conducts the final and highest level of agent detection. It also encompasses a wide range of technologies, including point detection technologies, which are anticipated to boost revenue growth in this segment. For instance, in July 2023, 908 Devices has introduced a novel remote area monitoring system called the MX908 Beacon, designed to detect and identify aerosolized and vapor threats. The Beacon is capable of monitoring the atmosphere for highly toxic substances, including fentanyl and Novichok nerve agents.
By end-user, hospital & clinics was the highest revenue-grossing segment in the global biodefense market in 2023 owing to the significant presence of extensive research and development facilities, the availability of historical patient data makes it particularly susceptible to infectious diseases, and increasing collaborations within market players. For instance, in May 2022, Emergent BioSolutions Inc. has revealed its commitment to acquire the exclusive global rights to TEMBEXA (brincidofovir) from Chimerix, Inc., as per a definitive agreement. TEMBEXA, the first antiviral to be approved by the United States Food and Drug Administration (FDA) for the treatment of smallpox in all age groups, is the focal point of this agreement. Additionally, ambulatory care centers is predicted to grow at fastest CAGR during the forecast period owing to the increasing healthcare expenditure, surge in funding for anthrax vaccine by major market players, and growing technological developments in healthcare sector.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing technological advancements, increasing awareness among the population, the presence of leading market players, surge in research & development activities and rising government initiatives. For instance, in August 2022, The U.S. Department of Health and Human Services (HHS) has played a key role in brokering an agreement between Bavarian Nordic and Grand River Aseptic Manufacturing (GRAM), a pharmaceutical contract manufacturer located in Michigan. This agreement is intended to establish the first domestic fill and finish production line for the JYNNEOS vaccine in the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising importance of biodefense, escalating risk posed by dangerous biological substances that lead to emergencies, the presence of sophisticated healthcare infrastructure, and surge in investments in research & development activities. For instance, in February 2022, Appili Therapeutics Inc. has disclosed securing over $10 million in funding to further the development of its biodefense vaccine candidate, ATI-1701, aimed at preventing infection with Francisella tularensis. This financial support is anticipated to enhance the company's standing and promote its expansion in the biodefense market.
Increasing regulatory approvals of biodefense products is predicted to boost the market growth during the forecast period. Biodefense encompasses a range of medical and military actions implemented to safeguard a nation's biosecurity against biological toxins or infectious agents. These agents may be employed with the aim of causing harm or infection in humans, animals, or the environment, potentially leading to acts of biological warfare. Typically, the biological agents utilized in bioterrorism involve living organisms such as bacteria, viruses, fungi, or toxins that are deliberately harnessed to induce illness and casualties, thereby causing social and economic disruption. For instance, in July 2023, Emergent BioSolutions Inc. has announced that the U.S. Food and Drug Administration (FDA) has given its approval for CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909. This approval covers the use of CYFENDUS for post-exposure prophylaxis in individuals aged 18 to 65 who are suspected or confirmed to have been exposed to Bacillus anthracis, provided it is administered in conjunction with the recommended antibacterial drugs.
By product, anthrax was the highest revenue-grossing segment in the global biodefense market in 2023 owing to the surge in anthrax outbreaks within the human population, rising favorable government initiatives, growing research & development partnerships in the respective areas of study, increasing mergers & acquisitions. For instance, in April 2022, Elusys Therapeutics, Inc., a biodefense business with commercial operations, has been formally acquired by Heat Biologics, Inc. Elusys is renowned for its development of the anthrax therapy ANTHIM (obiltoxaximab), which has received approval for use not only in the United States and Canada but also in Europe and the United Kingdom, where it is marketed as Obiltoxaximab SFL. Additionally, others is predicted to grow at fastest CAGR during the forecast period owing to the surge in number of infection cases attributed to the Zika and Ebola viruses, growing focus on the development of novel vaccines, and increasing research & development activities.
By detection device, assay was the highest revenue-grossing segment in the global biodefense market in 2023 owing to the increasing utilization of immunological assays, including techniques including Polymerase Chain Reaction (PCR), Immunochromatographic Tests (ICT), Next-Generation Sequencing (NGS) technology, & real-time RT-PCR and surge in research & development efforts. Additionally, identifier is predicted to grow at fastest CAGR during the forecast period. The identifier is the most crucial element of the detection architecture as it conducts the final and highest level of agent detection. It also encompasses a wide range of technologies, including point detection technologies, which are anticipated to boost revenue growth in this segment. For instance, in July 2023, 908 Devices has introduced a novel remote area monitoring system called the MX908 Beacon, designed to detect and identify aerosolized and vapor threats. The Beacon is capable of monitoring the atmosphere for highly toxic substances, including fentanyl and Novichok nerve agents.
By end-user, hospital & clinics was the highest revenue-grossing segment in the global biodefense market in 2023 owing to the significant presence of extensive research and development facilities, the availability of historical patient data makes it particularly susceptible to infectious diseases, and increasing collaborations within market players. For instance, in May 2022, Emergent BioSolutions Inc. has revealed its commitment to acquire the exclusive global rights to TEMBEXA (brincidofovir) from Chimerix, Inc., as per a definitive agreement. TEMBEXA, the first antiviral to be approved by the United States Food and Drug Administration (FDA) for the treatment of smallpox in all age groups, is the focal point of this agreement. Additionally, ambulatory care centers is predicted to grow at fastest CAGR during the forecast period owing to the increasing healthcare expenditure, surge in funding for anthrax vaccine by major market players, and growing technological developments in healthcare sector.
North America region is anticipated for the highest revenue share during the forecast period owing to the growing technological advancements, increasing awareness among the population, the presence of leading market players, surge in research & development activities and rising government initiatives. For instance, in August 2022, The U.S. Department of Health and Human Services (HHS) has played a key role in brokering an agreement between Bavarian Nordic and Grand River Aseptic Manufacturing (GRAM), a pharmaceutical contract manufacturer located in Michigan. This agreement is intended to establish the first domestic fill and finish production line for the JYNNEOS vaccine in the United States. Additionally, Asia Pacific region is predicted to grow at fastest CAGR during the forecast period owing to the rising importance of biodefense, escalating risk posed by dangerous biological substances that lead to emergencies, the presence of sophisticated healthcare infrastructure, and surge in investments in research & development activities. For instance, in February 2022, Appili Therapeutics Inc. has disclosed securing over $10 million in funding to further the development of its biodefense vaccine candidate, ATI-1701, aimed at preventing infection with Francisella tularensis. This financial support is anticipated to enhance the company's standing and promote its expansion in the biodefense market.
Segmentation: Biodefense Market Report 2023 - 2034
Biodefense Market Analysis & Forecast by Product 2023 - 2034 (Revenue USD Bn)
- Botulism
- Smallpox
- Anthrax
- Radiation/Nuclear
- Others
Biodefense Market Analysis & Forecast by Detection Device 2023 - 2034 (Revenue USD Bn)
- Identifiers
- Samplers
- Assays
- Detectors/Triggering Devices
Biodefense Market Analysis & Forecast by End-user 2023 - 2034 (Revenue USD Bn)
- Ambulatory Care Centers
- Hospitals & Clinics
- Others
Biodefense Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of LATAM
- Middle East & Africa
- South Africa
- GCC
- Rest of MEA
Table of Contents
1. Research Methodology
2. Introduction
4. Market Environment Analysis
5. Market Dynamics
7. Biodefense Market: Product Estimates & Trend Analysis
8. Biodefense Market: Detection Device Estimates & Trend Analysis
9. Biodefense Market: End-user Estimates & Trend Analysis
10. Regional Market Analysis
11. North America Biodefense Market
12. Europe Global Biodefense Market
13. Asia Pacific Global Biodefense Market
14. Latin America Global Biodefense Market
15. MEA Global Biodefense Market
16. Competitor Analysis
17. Company Profiles
Companies Mentioned
- Ology Bioservices
- Altimmune Inc.
- SIGA Technologies
- XOMA corporation
- Cleveland Biolabs
- Elusys Therapeutics Inc.
- Bavarian Nordic.
- Ichor Medical Systems.
- Alnylam Pharmaceuticals Inc
- Emergent Biosolutions Inc.
- Dynport Vaccine Company
- Dynavax Technologies Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 16.17 Billion |
| Forecasted Market Value ( USD | $ 30.19 Billion |
| Compound Annual Growth Rate | 5.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 12 |
